Title

Post-vaccination outcomes in COVID-19-associated chemosensory dysfunction

Running title:
COVID-19 vaccination and chemosensory dysfunction

Authors
Sachiko Koyama[1], Carla Mucignat-Caretta[2], Maria A. Klyuchnikova[3], Tatiana K. Laktionova[3], Svetlana Kopishinskaia[4], Ilya G. Kvasha[3], Junpeng Ye[5], Elena Cantone[6], Shima Parsa[7], Maria Dolors Guàrdia[8], Valentin Hivert[5], Solal Chauquet[5], Jingguo Chen[9], Giulio Centorame[5], Valentina Parma[10], Kathrin Ohla[11], Vera V. Voznessenskaya[3], Liang-Dar Hwang[5]

Affiliation
[1]Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
[2]Department of Molecular Medicine, University of Padova, Padova, Italy
[3]Severtsov Institute of Ecology & Evolution, Russian Academy of Sciences, Moscow, Russia
[4]Centre de Recherche du CHU de Québec, Laval University, Quebec, Canada
[5]Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia
[6]Department of Neuroscience, Reproductive and Dentistry Science, ENT Unit, Federico II University of Naples, Naples, Italy
[7]Shiraz Institute for Stem Cell & Regenerative Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
[8]Food Quality and Technology, IRTA-Food Research Institute, Monells, Spain
[9]The Department of Otolaryngology Head and Neck Surgery, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
[10]Monell Chemical Senses Center, Philadelphia, Pennsylvania, USA
[11]Science & Research, dsm-firmenich, Satigny, Switzerland

Correspondence to be sent to:
Liang-Dar Hwang, Institute for Molecular Bioscience, The University of Queensland, 306 Carmody Road, St Lucia, QLD 4072, Australia.
Email: d.hwang@uq.edu.au

ABSTRACT

Olfactory and taste dysfunction is a common symptom of COVID-19 and post-acute COVID-19 syndrome. Although vaccines have been suggested to influence chemosensory function both positively and negatively, data remain limited. This global survey assessed post-vaccination changes in chemosensory perception among individuals with COVID-19-related impairment. A multilingual online survey was distributed via convenience sampling (social media, email invitations to participants from a prior COVID-19 chemosensory study) between May 2022 and August 2023. Participants reported vaccination status, chemosensory function before and after each dose, and side effects. Data from 1,352 participants who received at least one dose were analyzed by vaccine brand, dose number, and pre-existing symptoms. Pfizer-BioNTech accounted for 46.2% of doses, followed by Sputnik V (16.3%), Moderna (15.4%), AstraZeneca (8.9%), and Sinopharm (7.4%). Among up to 49% of participants with pre-existing chemosensory impairments, 88-93% reported no change in general smell or taste, 3-8% reported improvement, and 2-7% reported worsening. Improvement rates were higher for parosmia (11-18%), phantosmia (20-29%), and taste distortion (12-21%). Across vaccine brands, Moderna's first dose was associated with the highest improvement rate for parosmia (24.5%). Side effects varied by vaccine type and were more frequent among individuals with worsened chemosensory symptoms. We observed symptomatic changes in parosmia, phantosmia, and taste distortion after vaccination, with brand-specific differences. These exploratory findings should be interpreted with caution, given reliance on self-reports, potential selection bias, and natural recovery. Future controlled studies with objective measures are needed to confirm these observations and clarify mechanisms.

Keywords: COVID-19, vaccines, olfactory disorders, parosmia, phantosmia, post-acute COVID-19 syndrome

INTRODUCTION

Following the outbreak of COVID-19 (Coronavirus disease 2019) caused by SARS-CoV-2, extensive effort was put into developing a vaccine. In less than one year, the first vaccines for COVID-19 were developed (see reviews(Chen et al., 2020; Kaur and Gupta, 2020; Russell et al., 2021)) and became available. SARS-CoV-2 vaccines can be classified into four types based on their antigen delivery mechanism: mRNA vaccines, adenovirus vector vaccines, inactivated virus vaccines, and recombinant protein vaccines (see reviews(Chen et al., 2020; Kaur and Gupta, 2020; Russell et al., 2021) as well as an overview by the World Health Organization (2025).

Many studies have described the symptoms of COVID-19 since the pandemic's onset (e.g., see these reviews(Li et al., 2020; Sun et al., 2020)). Acute COVID-19 can manifest with fever, cough, fatigue, shortness of breath, gastrointestinal symptoms, neurological symptoms, and chemosensory dysfunction, although asymptomatic infections have been reported as well(Lai et al., 2020; Zhao et al., 2020). Symptom recovery trajectories vary between individuals(Castanares-Zapatero et al., 2022; Cogliandro and Bonfanti, 2024; Golzardi et al., 2024; Makhluf et al., 2024), with symptoms persisting for 3 months post-infection being referred to as post-covid syndrome, post-acute sequelae of COVID-19, or Long COVID(Hastie et al., 2023; Sk Abd Razak et al., 2024), and later becoming a Medical Subject Headings (MeSH) term "Post-acute COVID-19 syndrome" (PCS). Due to the non-specific nature of PCS symptoms, prevalence estimates of PCS vary between studies, but recent data suggest it may affect as much as 45% of patients(Hastie et al., 2023; Sk Abd Razak et al., 2024).

Chemosensory dysfunction is a known symptom of COVID-19 and PCS, which includes impaired or distorted smell, taste, or chemesthetic perception(Cooper et al., 2020; Parma et al., 2020; Gerkin et al., 2021; Rouadi et al., 2021; Ohla et al., 2022; Nguyen et al., 2023). Although chemosensory dysfunctions were previously observed with other viral infections of the upper respiratory system, their occurrence was relatively rare compared to COVID-19(Koyama et al., 2021), in which up to 77 % of COVID-19 patients reported smell dysfunction and 44 % reported taste dysfunction(Butterworth, 1980; Hannum et al., 2020; Moein et al., 2020; Parma et al., 2020; Nguyen et al., 2023).

Soon after vaccines became available, changes in chemosensory function, both positively and negatively, were observed in case reports and cohort studies. A U.S.-based study using electronic medical records from >96 million individuals reported an incidence of disturbance of smell and/or taste of 0.003% and 0.009% after the first COVID-19 vaccination and after the first booster, respectively(Gallagher et al., 2024). Another UK-based cohort study focused on individuals experiencing PCS reported decreasing odds of loss of smell (-12.5%) and loss of taste (-9.2%) after receiving adenovirus vector or mRNA vaccines(Ayoubkhani et al., 2022). Temporary olfactory dysfunction after vaccination has been reported in isolated cases as well(Konstantinidis et al., 2020, 2021; Keir et al., 2021). While different vaccine types and brands have been associated with different side effects(Munro et al., 2021), the relationship between COVID-19 vaccines and changes in chemosensory perception has not been systematically and appropriately explored.

To fill this gap, we conducted a large global online survey to investigate the relationship between COVID-19 vaccination and PCS with a focus on within-participant changes in

chemosensory perception (*i.e.*, smell, taste, chemesthesis). We also analyzed participants with and without COVID-19-related chemosensory impairment and provided evidence for post-vaccination changes in distorted smell and taste as well as differences in PCS linked to vaccine types and brands.

MATERIALS AND METHODS

Survey design

The survey started with the date and brand of the vaccine received, followed by any side effects following vaccination. Participants selected side effects from a list (*i.e.*, fever, headache, chills, diarrhea, vomit, stomach ache, joint ache, cough, sore throat, shortness of breath, muscle soreness, lightheadedness, dizziness, nausea, fatigue, nasal congestion, burning nose, heart problems, sleep disturbances, blood clots, skin rash, menstrual changes, brain fog, and others) and reported the duration for the side effects. As our study focused on the chemical senses, the survey included detailed questions on the influences of vaccination on the senses of smell, taste, and chemesthesis. Participants reported whether these senses were affected by COVID-19 before vaccination, whether chemosensory dysfunction improved, worsened, or remained unchanged after vaccination, when the changes started, and the duration of the changes. They also reported whether they experienced parosmia, phantosmia, and distorted taste. Participants answered the questions for each dose of vaccine received.

The survey was deployed in English, Chinese (traditional and simplified), French, German, Italian, Japanese, Persian, Russian, and Spanish via the online platform Qualtrics hosted at Indiana University (see **Supplementary Materials** for the full survey in English). The study was approved by the Global Consortium for Chemosensory

Research (GCCR) Study Selection Team (ID: NDS006), the Institute Review Board of Indiana University (Protocol #: 15050), the Human Research Ethics Committee of the University of Queensland (Project ID: 2022/HE000839), and the Bioethics Committee at the A.N. Severtsov Institute of Ecology & Evolution of Russian Academy of Sciences (Protocol #.2022-63). It was pre-registered on the Open Science Framework (OSF)(Hwang et al., 2022).

Data collection and preprocessing

An online crowdsourced survey was distributed via social media, personal communication, GCCR newsletters (over 700 subscribers), and emails sent to over 6000 participants of prior GCCR studies(Parma et al., 2020; Gerkin et al., 2021) who consented to be recontacted. A total of 2,955 responses were received between May 2022 and August 2023. Open-text data collected from non-English surveys were translated into English and then merged for analysis. The data were preprocessed according to the pre-registered exclusion criteria. A total of 1,602 respondents were excluded because they did not review all questions before exiting the survey (n = 1,066), reported pre-existing health conditions (n = 228), did not receive a COVID-19 vaccine (n = 206), were pregnant after the outbreak of COVID (a known modulator of chemosensory ability(Cameron, 2014; Choo and Dando, 2017), n = 69) or younger than 18 years old (n = 33) (**Supplementary Figure 1**). Participants with pre-existing conditions were those who selected any of the following: “Neurological pathologies”, “Psychiatric pathologies”, “Head and neck trauma”, “Nasal sinus surgery”, “Head and neck radiation”, and “Impaired smell and taste perception” to the question “*Do you have below pre-existing conditions before COVID and/or before vaccination?*” We also excluded one participant who did not follow study instructions and provided information

irrelevant to the study. The final sample of 1,352 participants was included in the analyses. Participants were required to answer questions related to vaccination status but others were optional. This resulted in varying response numbers per question.

Data analysis

To characterize our sample, we compiled demographic data on age, sex, country of origin, vaccination status (*i.e.*, number of vaccination doses and boosters), brand of vaccine in terms of counts per category and percentages, and pre-vaccination chemosensory status, *i.e.*, whether chemosensory perception was affected by COVID-19 before vaccination. Different vaccine brands were grouped into four types: mRNA vaccines, adenovirus vector vaccines, inactivated virus vaccines, and recombinant protein vaccines (See **Supplementary Note**).

We reported the proportions of post-vaccination chemosensory changes (i.e., improvement, worsening, or no change) first with the whole sample, followed by separate analyses in participants with and without COVID-19-related chemosensory impairment before vaccination. We compared post-vaccination changes in smell and taste between participants with and without pre-existing chemosensory dysfunction using Fisher's exact test. Pre-existing chemosensory dysfunctions were defined as those with unresolved COVID-19-induced smell or taste loss, as well as those who experienced parosmia, phantosmia or distorted taste before vaccination. We also reported the timing and duration of changes in smell and taste.

To assess variation in outcomes across vaccine brands, we used Fisher's test of homogeneity, followed by pairwise comparisons between brands. A significance level of

$\alpha = 0.05$ was applied, and p-values were adjusted for multiple comparisons using Holm method. We performed binomial tests to compare the proportion of participants reporting improvement versus percent worsening for each vaccine brand and reported the two-sided p-values. To evaluate potential recall bias, we compared follow-up durations (i.e., the time differences between the vaccination date and survey day) across groups defined by post-vaccination chemosensory outcomes using one-way analysis of variance (ANOVA).

To examine the COVID-19 vaccine side effects, we first reported the frequency of each side effect by dose. To examine vaccine type-specific side effects, we calculated the incidence rate (proportion) of each side effect across the first three doses of vaccines of the same type. Within each vaccine type, we compared the incidence rate of a side effect between doses by means of the k-proportions test with the Marascuilo Procedure. Lastly, we compared the number of side effects between groups by post-vaccination changes in smell and taste using one-way ANOVA and pairwise t-tests.

The k-proportions test was performed using XLSTAT (version 2021.1.1), and all other analyses were performed in R (version 4.3.0) and RStudio (version 2023.03.0 Build 386).

RESULTS

Sample characteristics

This study included 1,352 participants from 52 countries, as reported in **Supplementary Table 1**. Participants represented six age groups: 5.11% of participants were 18 - 24 years old, 22.09% were 25 - 34, 23.94% were 35 - 44, 25.57% were 45 - 54, 16.31%

were 55 - 64, and 6.97% were more than 65 years old. Nearly half of the participants identified as cis women (46.99 %), followed by "Not specified" (*i.e.*, gender not disclosed; 35.54%) and cis men (18.09%); four participants identified as genderqueer or non-binary and one as trans man (**Supplementary Figure 2**). Pre-vaccination chemosensory impairments due to COVID-19 were reported in 599 of 1220 participants with complete responses for both taste and smell (49%), of which 416 reported impairments of both smell and taste, and the majority of the remaining participants reported solely smell impairment (**Supplementary Figure 3**). Pre-vaccination parosmia, phantosmia, and distorted taste were reported in 424, 265, and 380 participants, respectively (**Supplementary Tables 2 & 3)**.

Approximately half of the participants received two vaccine doses with one booster (46.1%), 28.2% received two doses with two boosters, 20% received two doses, and 5.8% received only one dose (see **Figure 1A** for the country-specific vaccination status). Among the 1,200 participants who received at least two doses, 44.2% (n = 531) received the Pfizer-BioNTech vaccine as the first two doses, which was the most frequent choice in most countries except Russia, Kazakhstan, Iran, the UK, and Switzerland, where the most common two doses were Sputnik V, Sinopharm, Astra-Zeneca or Moderna (**Figure 1B**). Among the 824 participants who received at least two doses and one booster, Pfizer-BioNTech double doses were most often combined with a booster from the same brand (n = 276, 33.5%) or with a booster from Moderna (n = 109, 13.2%). The third most common combination was two doses of Sputnik V plus a booster of Sputnik Light (n = 59, 7.2%, **Supplementary Table 4**). Pfizer-BioNTech accounted for 46.2% of all 3634 vaccine doses administered, followed by Sputnik V (16.3%), Moderna (15.4%), AstraZeneca (8.9%), and Sinopharm (7.4%).

Changes in chemosensory perception

Among all participants, 94% or more reported no changes in the senses of smell or taste perception after vaccination. After the first dose, 3% of participants reported improvement and 3% reported worsening in smell, while 2% and 3%, respectively, reported improvement and worsening in taste. Timing and duration of post-vaccination chemosensory changes were reported by 75 participants, of whom two-thirds reported changes started the day after vaccination, and most participants reported the changes lasted for longer than one month (**Supplementary Tables 2 and 3**).

Among participants with pre-existing smell or taste impairments due to COVID-19, approximately 90% reported no changes in the corresponding modality after vaccination. Depending on the number of doses, 3-8% reported an improvement, and 2-7% a worsening in smell or taste perception (**Figure 2**). Among participants without pre-existing chemosensory dysfunction, 97% or more reported no changes in any chemosensory modality after vaccination (**Supplementary Figure 4**; **Supplementary Table 5**). There was no difference in the time elapsed between the first vaccine dose and survey completion across participants who reported an improvement, worsening, or no changes in chemosensory outcomes (~20 months, $p > 0.05$; **Supplementary Table 6**).

For parosmia, phantosmia, and distorted taste, 66% or more participants did not experience any of them before or after vaccination, and 2% or fewer reported new onsets of these conditions (**Supplementary Tables 2 & 3**). Among participants with pre-existing impairments, depending on the number of doses, 11-18% reported improvements of parosmia, 20-29% of phantosmia, and 12-21% of distorted taste; 3% or

fewer reported worsening in these conditions (**Figure 3**).

Changes in chemosensory perception by vaccine brands

Among all participants, post-vaccination changes in smell differed between the most common five brands of vaccines, with the proportion of improvements after the first dose being the highest for Moderna (9.6%, 95% CI [4.4, 14.8]) and the lowest for Sputnik V (0.8%, 95% CI [-0.3, 1.9]); the proportion of worsening was lowest for Pfizer-BioNTech (1.3%, 95% CI [0.4, 2.3]) and highest for Sputnik V (4.5%, 95% CI [1.9, 7.1]). A similar pattern was observed after two doses of the same vaccines (**Table 1**). Results of country- and region-specific analyses are summarized in **Supplementary Table 7**. Post-vaccination changes in taste did not vary significantly between vaccine brands ($p > 0.05$; **Supplementary Table 8**). Among participants with pre-existing chemosensory dysfunction, no brand-specific associations were detected, possibly due to the small sample sizes.

When comparing post-vaccination improvements in parosmia among individuals with pre-existing parosmia, Moderna had the highest portion (24.5%, 95% CI [12.9, 36.1]) and Astra-Zeneca had the lowest (6.7%, 95% CI [-0.6, 14.0]) after the first dose (**Table 2**). For phantosmia, improvement was the highest with Moderna (34.4%, 95% CI [17.9, 50.8]) and lowest with Pfizer-BioNTech (17.1%, 95% CI [11.1, 23.1]) (**Table 3**). Regarding distorted taste, Sputnik showed the highest proportions of both improvements (20.0%, 95% CI [6.7, 33.3]) and worsening (8.6%, 95% CI [-0.7, 17.8]) (**Supplementary Table 9**). Results of country- and region-specific analyses are summarized in **Supplementary Tables 10-12**.

Side effects of vaccination

Amongst over 7,000 self-reported instances of adverse side effects of vaccination, the most common six symptoms were fatigue (incidence rate of 34.6% after first dose), headache (32.6%), fever (32.0%), muscle pain (29.0%), chills (25.2%), and joint pain (22.1%). Other side effects included menstrual changes (10% among cis women after the first dose), brain fog (6%), and sleep disturbance (5%) (**Supplementary Figure 5**; **Supplementary Table 13**).

While the incidence rate of side effects tended to decrease with each subsequent dose, there were differences between the types of vaccines. Between individuals who received the same type of vaccine for the first three doses (*i.e.*, two doses and one booster), the mRNA vaccine group ($n = 320$) showed no differences in incidence rates for the six most common side effects across three doses ($p > 0.05$). In contrast, a significant decrease in incidence rates was observed for fever and chill in the adenovirus vector vaccine group ($n = 80$) and headache in the inactivated virus vaccine group ($n = 51$) ($p < 0.05$) (**Supplementary Figure 6; Supplementary Tables 14 and 15**).

Lastly, we compared the number of side effects between individuals grouped by their post-vaccination changes in smell and taste. The number of side effects in the worsening group was significantly higher than in the improvement and no-change groups for both olfactory and gustatory modalities (**Supplementary Figure 7**; **Supplementary Table 16**).

DISCUSSION

Among individuals whose chemosensory perception was impaired by COVID-19, post-

vaccination changes were the most prominent in smell disorders, with over 20% and 11% of the affected individuals reporting an improvement in phantosmia and parosmia, respectively. Brand-stratified analyses showed a greater improvement of parosmia from Moderna compared to other brands, such as Pfizer-BioNTech, Astra-Zeneca, and Sputnik V. As for phantosmia, Moderna and Sputnik V both had the highest proportion of improvement and worsening. While these results could have potential application for personalized treatment, the sample sizes for the brand-stratified analyses were small, and there was no objective testing of smell and taste; hence, future investigation to replicate our findings is warranted.

More than 90% of individuals with pre-existing impaired taste and smell perception due to COVID-19 in this study reported no changes in general smell or taste after COVID-19 vaccination. Nevertheless, our results support findings from previous reports showing that COVID-19 vaccines can both improve and exacerbate chemosensory perception issues (Konstantinidis et al., 2020, 2021; Keir et al., 2021; Ayoubkhani et al., 2022) despite low frequencies. These results warrant further investigation into the role of vaccination in recovery trajectories.

The frequencies of side effects reported in the present study decreased with the vaccine doses for most types of vaccine, except for mRNA vaccines, with the side effects being the strongest after the second dose. In addition to common side effects, menstrual cycle changes were reported in more than 8% of female participants after each of the first three doses of the vaccine. While a recent report suggested that menstrual cycle changes could be related to the timing of vaccination(Edelman et al., 2024), our findings are observational and should be interpreted cautiously. Brain fog, a symptom of cognitive

decline, was consistently reported as a post-vaccination side effect in 4-6% of participants across vaccine doses in this study. A recent study showed that the odds of brain fog as a PCS symptom decreased with increasing vaccination rates (Feillet-Coudray et al., 2000). While several mechanisms behind COVID-19-related brain fog have been proposed (Shimohata, 2022), further longitudinal and mechanistic investigation is required to understand vaccine-related brain fog.

Limitations

Our study has several limitations. First, recruitment through social media and recontacting a previous cohort may have introduced selection bias, potentially overrepresenting individuals with more persistent symptoms or greater motivation to report outcomes. Second, self-selection bias is also possible, as those experiencing chemosensory changes may have been more likely to respond than those without symptoms. As a result, findings may not reflect fully generalizable population trends. Third, all data were self-reported, raising the possibility of recall bias and misclassification. While self-report methods have been successfully used to capture chemosensory function in recent studies(Parma et al., 2020; Gerkin et al., 2021; Ohla et al., 2022), they do not offer the precision of standardized psychophysical testing(Hannum et al., 2020). Fourth, the natural history of COVID-19-related chemosensory dysfunction often involves gradual recovery, making it difficult to distinguish vaccine-related effects from spontaneous improvement. Although no relationship was observed between time since vaccination and reported changes in smell or taste, the absence of longitudinal tracking and baseline objective measures limits causal interpretation. Fifth, the survey period spanned multiple infection waves and SARS-CoV-2 variants, which may have differed in their chemosensory impacts. Sixth,

sample sizes for brand-stratified analyses were small and uneven. For example, among participants with pre-existing parosmia, only 53 received Moderna and 45 received Sputnik V as their first dose, compared to 224 who received Pfizer-BioNTech. These imbalances reduce statistical power and limit the precision and generalizability of brand-specific findings. Finally, cross-country differences in healthcare access, vaccine brand availability, and cultural norms may have influenced both exposure and reporting. Together, these limitations constrain causal inference. Our findings should be interpreted as exploratory. Future longitudinal studies with standardized psychophysical assessments (e.g., Sniffn' Stick or taste strips), time-matched controls (e.g., comparing vaccinated and unvaccinated individuals with COVID-19-related chemosensory impairment during the same period), and regional factors are needed to validate these results and to differentiate vaccine-related effects from natural symptom resolution.

Clinical Significance

Our study investigated a unique need for tailored vaccination strategies that consider individual health profiles and regional differences in vaccine response. While the pathophysiological mechanisms underlying the effect of vaccines on chemosensory perception remain unclear (Lechien et al., 2024), the variability in side effects and chemosensory outcomes based on vaccine type underscores the importance of personalized approaches to vaccination, allowing healthcare providers to better manage patient expectations and improve compliance. The observation that mRNA vaccines maintain a consistent side effect profile while adenovirus vector vaccines show higher initial side effects that taper off suggests specific considerations for vaccine selection, particularly for patients with concerns about adverse reactions. Additionally, the potential therapeutic benefits of vaccination in improving certain chemosensory

dysfunctions, such as parosmia, phantosmia, and taste distortions, offer new avenues for managing these conditions in patients affected by COVID-19. These insights are crucial for informing public health strategies, addressing vaccine hesitancy, and optimizing vaccination campaigns to ensure broader and more effective protection against COVID-19.

CONCLUSIONS

This global survey provides preliminary evidence that COVID-19 vaccination may be associated with changes in chemosensory dysfunction among individuals previously affected by COVID-19, particularly for qualitative symptoms such as parosmia and phantosmia. Reported outcomes varied by vaccine type and brand, raising the possibility of variation in immunological or sensory responses. However, these observations are based on self-reported data and non-random sampling, and the study was not designed to establish causality. Findings should be interpreted with caution, as vaccine-related effects cannot be disentangled from the natural course of recovery. Further longitudinal and controlled studies using objective assessments are needed to establish causal relationships and support the development of targeted interventions.

ACKNOWLEDGEMENTS

LDH is supported by an Australian Research Council Early Discovery Researcher Award (DE240100014). We would like to thank Lisa Arvieu for assisting in translating the data collected from the French survey into English and Alyssa Bakke for emailing the survey to participants of previous GCCR studies.

AUTHORSHIP CONTRIBUTION

SK1, CMC, SK2, EC, MDG, JC, VP, VVV and LDH conceived the study. SK1, CMC, SK2, EC, MDG, JC, VP, KO, VVV and LDH designed the original survey. SK1, CMC, SK2, EC, SP, MDG, VH, SC, VP, JC, GC, KO, VVV and LDH translated and implemented the survey. SK1 and LDH set up the online survey. SK1, CMC, MAK, TKL, SK2, IGK, JY, MDG, VVV and LDH analyzed data. SK1, CMC, MAK, TKL, SK2, IGK, JY, MDG, VP, VVV and LDH interpreted data. SK1, CMC, SK2, EC, MDG, VP, JC, VVV and LDH administrated project. SK1, CMC, MAK, TKL, SK2, IGK, EC, MDG, VVV and LDH wrote the original manuscript. All authors reviewed and approved the final version of the manuscript. SK1, Sachiko Koyama; SK2, Svetlana Kopishinskaia.

CONFLICT OF INTEREST

KO works at dsm-firmenich. The company had no influence on the study design or interpretation of results. All other authors had no conflict of interest.

FUNDING

LDH is supported by an Australian Research Council Early Discovery Researcher Award (DE240100014).

DATA AVAILABILITY

The data underlying this article will be shared on reasonable request to the corresponding author.

REFERENCES

Ayoubkhani, D., Bermingham, C., Pouwels, K.B., Glickman, M., Nafilyan, V., Zaccardi, F., Khunti, K., Alwan, N.A., and Walker, A.S. 2022. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ. e069676.

Butterworth, J. 1980. Intracellular and extracellular alpha-D-mannosidase activity of cultured skin fibroblasts: relationship to cystic fibrosis. Clin Chim Acta. 108:347–353.

Cameron, E.L. 2014. Pregnancy and olfaction: a review. Front Psychol. 5:67.

Castanares-Zapatero, D., Chalon, P., Kohn, L., Dauvrin, M., Detollenaere, J., Maertens de Noordhout, C., Primus-de Jong, C., Cleemput, I., and Van den Heede, K. 2022. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 54:1473–1487.

Chen, W.-H., Strych, U., Hotez, P.J., and Bottazzi, M.E. 2020. The SARS-CoV-2 Vaccine Pipeline: an Overview. Curr Trop Med Rep. 7:61–64.

Choo, E., and Dando, R. 2017. The Impact of Pregnancy on Taste Function. Chem Senses. 42:279–286.

Cogliandro, V., and Bonfanti, P. 2024. Long COVID: lights and shadows on the clinical characterization of this emerging pathology. New Microbiol. 47:15–27.

Cooper, K.W., Brann, D.H., Farruggia, M.C., Bhutani, S., Pellegrino, R., Tsukahara, T., Weinreb, C., Joseph, P.V., Larson, E.D., Parma, V., et al. 2020. COVID-19 and the Chemical Senses: Supporting Players Take Center Stage. Neuron. 107:219–233.

Edelman, A., Boniface, E.R., Male, V., Cameron, S., Benhar, E., Han, L., Matteson, K.A., Lamsweerde, A. van, Pearson, J.T., and Darney, B.G. 2024. Timing of Coronavirus Disease 2019 (COVID-19) Vaccination and Effects on Menstrual Cycle Changes. Obstet Gynecol. 143:585–594.

Feillet-Coudray, C., Coudray, C., Bayle, D., Rock, E., Rayssiguier, Y., and Mazur, A. 2000. Response of diamine oxidase and other plasma copper biomarkers to various dietary copper intakes in the rat and evaluation of copper absorption with a stable isotope. Br J Nutr. 83:561–568.

Gallagher, T.J., Parikh, M., Herrera, K., Lin, M.E., and Hur, K. 2024. Association of COVID-19 Vaccination With Changes in Smell and Taste. Otolaryngol Head Neck Surg. 171:1240–1244.

Gerkin, R.C., Ohla, K., Veldhuizen, M.G., Joseph, P.V., Kelly, C.E., Bakke, A.J., Steele, K.E., Farruggia, M.C., Pellegrino, R., Pepino, M.Y., et al. 2021. Recent Smell Loss Is the Best Predictor of COVID-19 Among Individuals With Recent Respiratory Symptoms. Chem Senses. 46:bjaa081.

Golzardi, M., Hromić-Jahjefendić, A., Šutković, J., Aydin, O., Ünal-Aydın, P., Bećirević, T., Redwan, E.M., Rubio-Casillas, A., and Uversky, V.N. 2024. The Aftermath of COVID-19: Exploring the Long-Term Effects on Organ Systems. Biomedicines. 12:913.

Hannum, M.E., Ramirez, V.A., Lipson, S.J., Herriman, R.D., Toskala, A.K., Lin, C., Joseph, P.V., and Reed, D.R. 2020. Objective sensory testing methods reveal a higher prevalence of olfactory loss in COVID-19–positive patients compared to subjective methods: A systematic review and meta-analysis. Chemical Senses. bjaa064.

Hastie, C.E., Lowe, D.J., McAuley, A., Mills, N.L., Winter, A.J., Black, C., Scott, J.T., O'Donnell, C.A., Blane, D.N., Browne, S., et al. 2023. True prevalence of long-COVID in a nationwide, population cohort study. Nat Commun. 14:7892.

Hwang, L.-D., Farruggia, M.C., Cantone, E., Chen, J., Joseph, P.V., Voznessenskaya, V., and Kopishinskaia, S. 2022. Influences of COVID-19 vaccination on post-acute sequelae of COVID-19.

Kaur, S.P., and Gupta, V. 2020. COVID-19 Vaccine: A comprehensive status report. Virus Res. 288:198114.

Keir, G., Maria, N.I., and Kirsch, C.F.E. 2021. Unique Imaging Findings of Neurologic Phantosmia Following Pfizer-BioNtech COVID-19 Vaccination: A Case Report. Top Magn Reson Imaging. 30:133–137.

Konstantinidis, I., Delides, A., Tsakiropoulou, E., Maragoudakis, P., Sapounas, S., and Tsiodras, S. 2020. Short-Term Follow-Up of Self-Isolated COVID-19 Patients with Smell and Taste Dysfunction in Greece: Two Phenotypes of Recovery. ORL J Otorhinolaryngol Relat Spec. 1–9.

Konstantinidis, I., Tsakiropoulou, E., Hähner, A., With, K. de, Poulas, K., and Hummel, T. 2021. Olfactory dysfunction after coronavirus disease 2019 (COVID-19) vaccination. Int Forum Allergy Rhinol. 11:1399–1401.

Koyama, S., Kondo, K., Ueha, R., Kashiwadani, H., and Heinbockel, T. 2021. Possible Use of Phytochemicals for Recovery from COVID-19-Induced Anosmia and Ageusia. IJMS. 22:8912.

Lai, C.-C., Liu, Y.H., Wang, C.-Y., Wang, Y.-H., Hsueh, S.-C., Yen, M.-Y., Ko, W.-C.,

and Hsueh, P.-R. 2020. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 53:404–412.

Lechien, J.R., Diallo, A.O., Dachy, B., Le Bon, S.D., Maniaci, A., Vaira, L.A., and Saussez, S. 2024. COVID-19: Post-vaccine Smell and Taste Disorders: Report of 6 Cases. Ear Nose Throat J. 103:NP104–NP107.

Li, L.-Q., Huang, T., Wang, Y.-Q., Wang, Z.-P., Liang, Y., Huang, T.-B., Zhang, H.-Y., Sun, W., and Wang, Y. 2020. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 92:577–583.

Makhluf, H., Madany, H., and Kim, K. 2024. Long COVID: Long-Term Impact of SARS-CoV2. Diagnostics (Basel). 14:711.

Moein, S.T., Hashemian, S.M., Mansourafshar, B., Khorram□Tousi, A., Tabarsi, P., and Doty, R.L. 2020. Smell dysfunction: a biomarker for COVID□19. Int Forum Allergy Rhinol. 10:944–950.

Munro, A.P.S., Janani, L., Cornelius, V., Aley, P.K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., et al. 2021. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. The Lancet. 398:2258–2276.

Nguyen, H., Albayay, J., Höchenberger, R., Bhutani, S., Boesveldt, S., Busch, N.A., Croijmans, I., Cooper, K.W., De Groot, J.H.B., Farruggia, M.C., et al. 2023. Covid-19 affects taste independent of taste–smell confusions: results from a combined chemosensory home test and online survey from a large global cohort. Chemical Senses. 48:bjad020.

Ohla, K., Veldhuizen, M.G., Green, T., Hannum, M.E., Bakke, A.J., Moein, S.T., Tognetti, A., Postma, E.M., Pellegrino, R., Hwang, D.L.D., et al. 2022. A follow-up on quantitative and qualitative olfactory dysfunction and other symptoms in patients recovering from COVID-19 smell loss. Rhinology. 60:207–217.

Parma, V., Ohla, K., Veldhuizen, M.G., Niv, M.Y., Kelly, C.E., Bakke, A.J., Cooper, K.W., Bouysset, C., Pirastu, N., Dibattista, M., et al. 2020. More Than Smell-COVID-19 Is Associated With Severe Impairment of Smell, Taste, and Chemesthesis. Chem Senses. 45:609–622.

Rouadi, P.W., Idriss, S.A., and Bousquet, J. 2021. Olfactory and taste dysfunctions in COVID-19. Curr Opin Allergy Clin Immunol. 21:229–244.

Russell, R.L., Pelka, P., and Mark, B.L. 2021. Frontrunners in the race to develop a SARS-CoV-2 vaccine. Can J Microbiol. 67:189–212.

Shimohata, T. 2022. Neuro-COVID-19. Clin Exp Neuroimmunol. 13:17–23.

Sk Abd Razak, R., Ismail, A., Abdul Aziz, A.F., Suddin, L.S., Azzeri, A., and Sha'ari, N.I. 2024. Post-COVID syndrome prevalence: a systematic review and meta-analysis. BMC Public Health. 24:1785.

Sun, P., Qie, S., Liu, Z., Ren, J., Li, K., and Xi, J. 2020. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis. J Med Virol. 92:612–617.

World Health Organization. 2025. COVID-19 vaccine tracker and landscape. World Health Organization. Available from: https://www.who.int/teams/blueprint/covid-19/covid-19-vaccine-tracker-and-landscape [accessed 11 September 2025].

Zhao, D., Wang, M., Wang, M., Zhao, Y., Zheng, Z., Li, X., Zhang, Y., Wang, T., Zeng, S., Hu, W., et al. 2020. Asymptomatic infection by SARS-CoV-2 in healthcare workers: A study in a large teaching hospital in Wuhan, China. Int J Infect Dis. 99:219–225.

FIGURES



Figure 1. Distribution of vaccination status of participants (A) and combinations of the first two doses received (B) in different countries. Only countries with ≥10 respondents were included. The number in brackets represents the total number of vaccinated participants per country.



Figure 2. Changes in the senses of smell and taste after each dose of vaccine in participants with pre-existing chemosensory impairment due to COVID-19. The number of participants per condition for the first three doses is shown in parentheses.



Figure 3. Changes in parosmia/phantosmia/distorted taste after each dose of vaccine in participants with pre-existing sensory impairment due to COVID-19. The number of participants per condition for the first three doses is shown in parentheses.

TABLES

Table 1. Changes in smell after the first dose and the second dose of the five most common vaccine brands.

After the first dose of vaccine						
Brands	**Vaccinated participants**	**Improved smell**		**Worsened smell**		**Improved vs worsened[f]**
	N	**N**	**Proportion**	**N**	**Proportion**	**P**
Pfizer-BioNTech[a]	598	18	3.0%	8	1.3%	0.08
Sputnik V[b]	246	2	0.8%	11	4.5%	0.02
Astra-Zeneca[b]	159	7	4.4%	7	4.4%	1
Moderna[a]	125	12	9.6%	4	3.2%	0.08
Sinopharm[c]	108	2	1.9%	2	1.9%	1
Total	1236	41	3.3%	32	2.6%	0.35
Fisher's Exact test of homogeneity, p-value [d]		$p < 0.001$		$p = 0.03$		
Significant post hoc test results, p-value unadjusted[d]		Pfizer-BioNTech vs Moderna, $p = 0.002$; Sputnik V vs Astra-Zeneca, $p = 0.03$; Sputnik V vs Moderna, $p < 0.001$; Moderna vs Sinopharm, $p = 0.01$		Pfizer-BioNTech vs Sputnik V, $p = 0.009$; Pfizer-BioNTech vs Astra-Zeneca, $p = 0.02$		
Significant post hoc test results, p-value adjusted[e]		Pfizer-BioNTech vs Moderna, $p = 0.02$; Sputnik V vs Moderna, $p < 0.001$		NS		
After the second dose of vaccine						
Pfizer-BioNTech[a] × 2	529	14	2.6%	4	0.8%	0.03
Sputnik V[b] × 2	194	3	1.5%	9	4.6%	0.15
Astra-Zeneca[b] × 2	108	3	2.8%	3	2.8%	1
Sinopharm[c] × 2	102	1	1.0%	2	2.0%	1
Moderna[a] × 2	99	7	7.1%	5	5.1%	0.77
Total	1032	28	2.7%	23	2.2%	0.58
Fisher's Exact test of homogeneity, p-value[d]		$p = 0.09$		$p = 0.002$		
Significant post hoc test results, p-value unadjusted[e]		Pfizer-BioNTech vs Moderna, $p = 0.03$; Sputnik V vs Moderna, $p = 0.03$; Sinopharm vs Moderna, $p = 0.03$		Pfizer-BioNTech vs Sputnik V, $p = 0.002$; Pfizer-BioNTech vs Moderna, $p = 0.007$		
Significant post hoc test results, p-value adjusted[e]		NS		Pfizer-BioNTech vs Sputnik V, $p = 0.02$		

Note: Brands with ≥95 respondents were included. All participants who received the first two doses of the same vaccine were included in the analysis of post-vaccination changes after the first dose of vaccine. [a]mRNA type vaccines; [b]adenovirus vector vaccines; [c]inactivated virus vaccines. [d]Fisher's test of homogeneity was used to compare the proportions of improvement or worsening between all groups. The following pairwise comparisons (post hoc) were also conducted with Fisher's test. [e]p-values are reported either unadjusted or adjusted for multiple comparisons using Holm method. [f]Binomial tests comparing the % improvement and % worsening with two-sided p-values reported. NS, no significant difference between all pairs.

Table 2. Post-vaccination changes in pre-existing parosmia by vaccine brands.

Brands	Vaccinated participants	Improved parosmia		Worsened parosmia		Improved vs worsened[e]
	N	N	Proportion	N	Proportion	P
After the first dose of vaccine						
Pfizer-BioNTech[a]	224	20	8.9%	4	1.8%	0.002
Moderna[a]	53	13	24.5%	0	0%	<0.001
Sputnik V[b]	53	8	15.1%	4	7.5%	0.39
Astra-Zeneca[b]	45	3	6.7%	1	2.2%	0.63
Total	375	44	11.7%	9	2.4%	<0.001
Fisher's Exact test of homogeneity, p-value[c]		p = 0.01		p = 0.08		
Significant post hoc test results, p-value unadjusted[d]		Pfizer-BioNTech vs Moderna, p = 0.004; Moderna vs Astra-Zeneca, p = 0.03		Pfizer-BioNTech vs Sputnik, p = 0.046		
Significant post hoc test results, p-value adjusted[d]		Pfizer-BioNTech vs Moderna, p = 0.02		NS		
After the second dose of vaccine						
Pfizer-BioNTech[a] × 2	176	24	13.6%	1	0.6%	<0.001
Moderna[a] × 2	35	5	14.3%	0	0%	0.06
Sputnik V[b] × 2	38	6	15.8%	3	7.9%	0.51
Astra-Zeneca[b] × 2	25	1	4.0%	1	4.0%	1
Total	274	36	13.1%	5	1.8%	<0.001
Fisher's Exact test of homogeneity, p-value[c]		p = 0.54		p = 0.02		
Significant post hoc test results, p-value unadjusted[d]		NS		Pfizer-BioNTech vs Sputnik V, p = 0.02		
Significant post hoc test results, p-value adjusted[d]		NS		NS		

Note: The most common 4 brands were included. All participants who received the first two doses of the same vaccine were included in the analysis of post-vaccination changes after the first dose of vaccine. [a]mRNA type vaccines; [b]adenovirus vector vaccines. [c]Fisher's test of homogeneity was used to compare the proportions of improvement or worsening between all groups. The following pairwise comparisons (post hoc) were also conducted with Fisher's test. [d]p-values are reported either unadjusted or adjusted for multiple comparisons using Holm method. [e]Binomial tests comparing the % improvement and % worsening with two-sided p-values reported. NS, no significant difference between all pairs.

Table 3. Post-vaccination changes in pre-existing phantosmia by vaccine brands

Brands	Vaccinated participants	Improved phantosmia		Worsened phantosmia		Improved vs worsened[e]
	N	N	Proportion	N	Proportion	P
After the first dose of vaccine						
Pfizer-BioNTech[a]	152	26	17.1%	4	2.6%	<0.001
Moderna[a]	32	11	34.4%	3	9.4%	0.06
Astra-Zeneca [b]	30	6	20.0%	0	0%	0.03
Sputnik V[b]	23	6	26.1%	2	8.7%	0.29
Total	237	49	20.7%	9	3.8%	<0.001
Fisher's Exact test of homogeneity, p-value[c]		p = 0.15		p = 0.09		
Significant post hoc test results, p-value unadjusted[d]		Pfizer-BioNTech vs Moderna, p = 0.049		NS		
Significant post hoc test results, p-value adjusted[d]		NS		NS		
After the second dose of vaccine						
Pfizer-BioNTech[a] **× 2**	119	21	17.6%	6	5.0%	0.006
Moderna[a] **× 2**	22	7	31.8%	1	4.5%	0.07
Astra-Zeneca[b] **× 2**	18	1	5.6%	0	0%	1
Sputnik V[b] **× 2**	14	5	35.7%	0	0%	0.06
Total	173	34	19.7%	9	5.2%	<0.001
Fisher's exact test of homogeneity, p-value[c]		p = 0.07		p = 1		
Significant post hoc test results, p-value unadjusted[d]		NS		NS		
Significant post hoc test results, p-value adjusted[d]		NS		NS		

Note: The most common 4 brands were included. All participants who received the first two doses of the same vaccine were included in the analysis of post-vaccination changes after the first dose of vaccine. [a]mRNA type vaccines; [b]adenovirus vector vaccines. [c]Fisher's test of homogeneity was used to compare the proportions of improvement or worsening between all groups. The following pairwise comparisons (post hoc) were also conducted with Fisher's test. [d]p-values are reported either unadjusted or adjusted for multiple comparisons using Holm method. [e]Binomial tests comparing the % improvement and % worsening with two-sided p-values reported. NS, no significant difference between all pairs.